Literature DB >> 11235923

Gabapentin in the treatment of cocaine dependence: a case series.

H Myrick1, S Henderson, K T Brady, R Malcolm.   

Abstract

BACKGROUND: Although multiple medications have been studied for the treatment of cocaine dependence, no medication has been shown to have a robust effect on craving and use. This pilot project was designed to evaluate the safety and tolerability of gabapentin in subjects with cocaine dependence.
METHOD: Thirty cocaine-dependent subjects (DSM-IV criteria) were enrolled in an 8-week, open-label trial of 1,200 mg/day of gabapentin in divided doses. Urine drug screens, subjective measures of craving, and cocaine use interviews were conducted at each weekly visit.
RESULTS: Baseline rating of amount and frequency of craving decreased significantly by week 8 (78% vs. 25% for amount, p = .000; 74% vs. 23% for frequency, p = .004). Positive urine drug screens for cocaine decreased from 86% at baseline to 29% at weeks 4 and 8. There were no reports of significant side effects or adverse events.
CONCLUSION: This pilot study indicates that gabapentin is safe and well tolerated and may be beneficial in the treatment of cocaine dependence. A placebo-controlled trial would be of interest.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11235923     DOI: 10.4088/jcp.v62n0105

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats.

Authors:  Małgorzata Filip; Małgorzata Frankowska; Magdalena Zaniewska; Anna Gołda; Edmund Przegaliński; Jerzy Vetulani
Journal:  Psychopharmacology (Berl)       Date:  2007-01-26       Impact factor: 4.530

Review 3.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

4.  Chronic cocaine exposure in the SCID mouse model of HIV encephalitis.

Authors:  W C Griffin; L D Middaugh; W R Tyor
Journal:  Brain Res       Date:  2006-12-26       Impact factor: 3.252

Review 5.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 6.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

Review 7.  [Pain therapy in addicted patients].

Authors:  C Hampel; M Schenk; H Göbel; I Gralow; S M Grüsser; C Jellinek; G Ernst; K Hermanns; J Gölz; W Poser; M Strumpf; E A M Neugebauer; C Spies
Journal:  Schmerz       Date:  2006-09       Impact factor: 1.107

8.  Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.

Authors:  Xiao-Qing Peng; Xia Li; Jie Li; P Veeraraghavan Ramachandran; Pravin D Gagare; Debarshi Pratihar; Charles R Ashby; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drug Alcohol Depend       Date:  2007-12-11       Impact factor: 4.492

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 10.  Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  Curr Drug Abuse Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.